Candel Therapeutics (CADL) Common Equity (2020 - 2023)
Historic Common Equity for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $23.0 million.
- Candel Therapeutics' Common Equity fell 5583.48% to $23.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $23.0 million, marking a year-over-year decrease of 5583.48%. This contributed to the annual value of $47.7 million for FY2022, which is 2560.61% down from last year.
- Candel Therapeutics' Common Equity amounted to $23.0 million in Q3 2023, which was down 5583.48% from $30.8 million recorded in Q2 2023.
- In the past 5 years, Candel Therapeutics' Common Equity ranged from a high of $64.1 million in Q4 2021 and a low of -$43.2 million during Q2 2021
- Its 4-year average for Common Equity is $34.3 million, with a median of $47.7 million in 2022.
- As far as peak fluctuations go, Candel Therapeutics' Common Equity soared by 37220.52% in 2021, and later crashed by 5583.48% in 2023.
- Candel Therapeutics' Common Equity (Quarter) stood at -$23.6 million in 2020, then skyrocketed by 372.21% to $64.1 million in 2021, then fell by 25.61% to $47.7 million in 2022, then crashed by 51.75% to $23.0 million in 2023.
- Its Common Equity stands at $23.0 million for Q3 2023, versus $30.8 million for Q2 2023 and $39.7 million for Q1 2023.